| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 09/12/2002 | WO2002016410A3 Peptide selection method |
| 09/12/2002 | WO2002012346A3 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 09/12/2002 | WO2001068078A3 Immunostimulatory polynucleotide sequences for use in suppressing hepatitis virus infection |
| 09/12/2002 | WO2001045681A3 Naphthoquinone derivatives as cd45 inhibitors |
| 09/12/2002 | WO2001041797A9 Systemic immune response induced by mucosal administration of l ipid-tailed polypeptides without adjuvant |
| 09/12/2002 | WO2001034170A9 Phytotherapeutic composition |
| 09/12/2002 | WO2001017557A9 Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents |
| 09/12/2002 | WO2001015694A9 Extended duration light activated cancer therapy |
| 09/12/2002 | US20020128471 Useful for treating cellular hyperproliferation |
| 09/12/2002 | US20020128448 Monoclonal antibody for use in the treatment of cell proliferative defects |
| 09/12/2002 | US20020128444 Controling abberant inflamatory response; obtain animal, incubate with modulator of inflammation, monitor animal for adjustment in inflammatory response |
| 09/12/2002 | US20020128442 Human proteins STAM2a and STAM2b, and cDNAs encoding these molecules |
| 09/12/2002 | US20020128436 Therapeutic composition for use in the treatment of autoimune and rheumatic diseases |
| 09/12/2002 | US20020128317 Administering diacerein or rhein to treat inflammatory and autoimmune conditions characterized by an increased IL-1 and or TNF alpha level |
| 09/12/2002 | US20020128306 Programmed cell death; expansion of hematopoietic cells, for prolonging viability of an organ for transplantation, and maintaining viability of cell lines used in bioproduction |
| 09/12/2002 | US20020128303 Injection with a photodynamic compound having tumor selective uptake which is activated at a particular light frequency; injection with a xanthenone-4-acetic acid or salt; exposing the tumor to light at the activation frequency |
| 09/12/2002 | US20020128279 Potassium channel blocking agents |
| 09/12/2002 | US20020128271 N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| 09/12/2002 | US20020128250 Modulating the expression of a gene |
| 09/12/2002 | US20020128240 Treatment of hyperproliferative diseases using active vitamin D analogues |
| 09/12/2002 | US20020128225 Methods and products related to pulmonary delivery of polysaccharides |
| 09/12/2002 | US20020128217 Therapeutic use of cis-element decoys in vivo |
| 09/12/2002 | US20020127715 Adjusting gene expression in preferential cells; obtain pluripotent cells, transform, monitor gene expression, compare to control, detect adjustment in gene expression |
| 09/12/2002 | US20020127713 Specific tolerance in transplantation |
| 09/12/2002 | US20020127694 2786, a novel human aminopeptidase |
| 09/12/2002 | US20020127676 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 09/12/2002 | US20020127668 Polypeptide for use in the diagnosis and treatment of cancer, nervous system and vessicular transport disorders |
| 09/12/2002 | US20020127656 DNA repair polypeptides and methods of use |
| 09/12/2002 | US20020127647 ATP-binding cassette transporter-like molecules and uses thereof |
| 09/12/2002 | US20020127645 Secretory immunoglobulin produced by single cells and methods for making and using same |
| 09/12/2002 | US20020127553 Apoptin-associating protein |
| 09/12/2002 | US20020127248 Using rapamycin compound for therapy and prophylaxis of neointimal proliferation and thickening |
| 09/12/2002 | US20020127246 Use of herpes vectors for tumor therapy |
| 09/12/2002 | US20020127243 Administering dietary supplement comprising soybean, mushroom and mung bean or extracts to ameliorate at least one effect of malignancy or viral infection |
| 09/12/2002 | US20020127240 Leptospiral rare outer membrane proteins |
| 09/12/2002 | US20020127235 Identification and molecular characterization of proteins, expressed in the Ixodes ricinus salivary glands |
| 09/12/2002 | US20020127232 Activating alpha 2-macroglobulin by incubation with a nucleophilic compound to form nucleophile-activated alpha 2-macroglobulin, removing excess of nucleophilic compound, incubating activated alpha-2 macroglobulin with biomolecule |
| 09/12/2002 | US20020127231 Extracellular domains of a heterodimeric protein operatively linked to immunoglobulin heavy and light chain polypeptides |
| 09/12/2002 | US20020127208 Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease |
| 09/12/2002 | US20020127205 Immunoregulatory molecule expressed by the cell(s) are capable of inhibiting T cell activation and/or natural killer cell-mediated immune response against the cell upon transplantation into a recipient subject |
| 09/12/2002 | US20020127198 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | US20020127188 Composition for pulmonary administration comprising a drug and a hydrophobic amino acid |
| 09/12/2002 | DE10111877A1 Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate New imidazolidine derivatives, their preparation, their use and pharmaceutical compositions containing them |
| 09/12/2002 | CA2441476A1 Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| 09/12/2002 | CA2440803A1 Modulators of chemokine receptor activity |
| 09/12/2002 | CA2440642A1 Dimeric isoflavones |
| 09/12/2002 | CA2440161A1 Inhibitor of monoamine uptake |
| 09/12/2002 | CA2439941A1 Secreted proteins |
| 09/12/2002 | CA2439926A1 Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity |
| 09/12/2002 | CA2439852A1 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| 09/12/2002 | CA2439849A1 Antagonists of mcp-1 function and methods of use thereof |
| 09/12/2002 | CA2439802A1 Immune response potentiation |
| 09/12/2002 | CA2439691A1 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| 09/12/2002 | CA2439687A1 Use of certain steroids for treatment of blood cell deficiencies |
| 09/12/2002 | CA2439625A1 Compositions of multimeric profilin for diagnosis and treatment of allergies |
| 09/12/2002 | CA2439594A1 Interleukin-8 homologous polypeptides and therapeutic uses thereof |
| 09/12/2002 | CA2439205A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439203A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439200A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439197A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439196A1 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | CA2439195A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2439192A1 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | CA2438737A1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 09/12/2002 | CA2438326A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | CA2437594A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | CA2434066A1 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 09/12/2002 | CA2433933A1 Use of lp82 to treat hematopoietic disorders |
| 09/12/2002 | CA2431549A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 09/11/2002 | EP1239039A1 Novel polypeptide and dna thereof |
| 09/11/2002 | EP1239034A2 Large circular target-specific antisense nucleic acids |
| 09/11/2002 | EP1239032A1 Lactic acid bacteria as agents for treating and preventing allergy |
| 09/11/2002 | EP1238674A2 Treatment of immunologic and hematologic disorders with IGFBP alone or complexed with IGF |
| 09/11/2002 | EP1238666A2 Use of xanthenone-4-acetic acid in the manufacture of a medicament in the treatment of hyperproliferative disorders |
| 09/11/2002 | EP1238095A2 Compositions and methods for caspase-induced apoptosis |
| 09/11/2002 | EP1238082A2 Ifn-alpha homologues |
| 09/11/2002 | EP1238077A1 Tnfr/opg-like molecules and uses thereof |
| 09/11/2002 | EP1238070A2 Therapeutically useful synthetic oligonucleotides |
| 09/11/2002 | EP1238066A2 Masp-3, a complement-fixing enzyme, and uses for it |
| 09/11/2002 | EP1237929A1 Dendritic cell-specific antibodies |
| 09/11/2002 | EP1237919A1 Interferon-alpha induced gene |
| 09/11/2002 | EP1237914A1 Methods for improving secondary metabolite production in fungi |
| 09/11/2002 | EP1237913A2 Antigen preparations |
| 09/11/2002 | EP1237912A2 Five-helix protein |
| 09/11/2002 | EP1237902A1 Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase |
| 09/11/2002 | EP1237892A2 Method for producing epinastine hydrochloride in the high-melting crystal modification |
| 09/11/2002 | EP1237891A1 Heterocyclic dihydropyrimidines as potassium channel inhibitors |
| 09/11/2002 | EP1237887A1 9-(piperazinylalkyl)carbazoles as bax-modulators |
| 09/11/2002 | EP1237880A2 Pyrazine based inhibitors of glycogen synthase kinase 3 |
| 09/11/2002 | EP1237877A2 Carboxamide-substituted benzimidazol derivatives, methods for the production thereof and their use as medicaments |
| 09/11/2002 | EP1237876A1 N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses |
| 09/11/2002 | EP1237874A2 Selective neurokinin antagonists |
| 09/11/2002 | EP1237845A1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| 09/11/2002 | EP1237582A2 Methods for introducing genes into mammalian subjects |
| 09/11/2002 | EP1237578A2 Micro-cluster liquids and methods of making and using them |
| 09/11/2002 | EP1237575A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 09/11/2002 | EP1237574A2 Antigen delivery |
| 09/11/2002 | EP1237573A1 Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory iga's |
| 09/11/2002 | EP1237567A2 Method for administering a cytokine to the central nervous system and the lymphatic system |
| 09/11/2002 | EP1237548A1 Il-8 receptor antagonists |